BMO Capital analyst Evan Seigerman has maintained their neutral stance on BMY stock, giving a Hold rating on October 21.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Evan Seigerman’s rating is based on a combination of factors that suggest Bristol-Myers Squibb’s stock is currently fairly valued. The company’s ongoing launch of Cobenfy in the schizophrenia market shows some positive momentum, with a notable 4.9% increase in weekly prescriptions. However, despite this growth, the overall prescription numbers are still not sufficient to surpass the consensus revenue estimates for the third quarter of 2025.
Additionally, the analysis highlights the stable cash flows from Bristol-Myers Squibb’s immuno-oncology and hematology businesses, which contribute to the company’s financial stability. However, the new product launches are progressing at a slower pace than anticipated, which tempers expectations for rapid growth. Given these factors, the Hold rating reflects a balanced view of the company’s current valuation and future prospects.
In another report released on October 21, Bernstein also assigned a Hold rating to the stock with a $58.00 price target.